Fondazione MBBM - Ematologia Pediatrica
- Address
- Via Pergolesi 33, 20900 Monza, Italy
Fondazione MBBM - Pediatric Hematology Center
Fondazione MBBM's Pediatric Hematology department is a specialized clinical research center dedicated to advancing treatment strategies for childhood blood cancers. The center focuses on developing innovative therapeutic approaches for high-risk pediatric hematologic malignancies, with particular expertise in relapsed and refractory disease management.
- High-risk acute lymphoblastic leukemia in pediatric populations
- Novel targeted therapies including antibody-drug conjugates
- CD22-positive B-cell precursor malignancies
The center is actively involved in phase 2 superiority trials evaluating Inotuzumab Ozogamicin monotherapy for children aged 1 to 18 years with high-risk first bone marrow relapse of B-cell precursor acute lymphoblastic leukemia. This research represents a commitment to identifying more effective and potentially less toxic treatment alternatives for children facing challenging relapse scenarios in CD22-positive ALL.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondazione MBBM - Ematologia Pediatrica
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 2 Randomized Study of Inotuzumab Ozogamicin Monotherapy Versus ALLR3 Regimen in Pediatric High-Risk First Relapse CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia | Pfizer Inc. | Phase II | Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Crisantaspase | 1 | Unknown | 2023-05-13 | 2023-05-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.